Gapping up
In reaction to strong earnings/guidance: CONN +10.7%.
M&A news: NPSP +18.7% (Shire (SHPG) has secured funding for $5 bln NPSP bid, according to reports), PL +17.7% (Dai-ichi Life Insurance considering acquisition of PL, according to reports), BRCM +14% (to explore strategic alternatives for Cellular Baseband Business; reaffirms Q2 revenue guidance), HCT +10.9% (to be acquired by Ventas (VTR) for $2.6 bln, or $11.33 per HCT share),AMRI +3.1% (to acquire Oso Biopharmaceuticals Manufacturing for $110 million in cash; co anticipates the acquisition will be accretive to 2014 earnings), AHL +2.6% (Endurance Specialty (ENH) increases Proposal to Acquire Aspen Insurance Holdings (AHL) to $49.50 Per Share in Cash), SQNM +2% (announces its bioscience business was acquired by Agena Bioscience).
Select Biotech/pharma related names showing strength following ASCO: ARIA +14.6%, IMUC +11.9%, PCYC +6.8%, AVEO +5.4%, RXDX +3.6%, PBMD +0.7%, AZN +0.7%, BMY +0.5%.
Other news: LIQD +7.4% (MSDC Management discloses 10.6% passive stake in 13G filing), CANF +6.3% (announces that the US FDA has agreed with its Phase ii liver cancer protocol ), OMER +6.2% (receives FDA approval of Omidria for use in cataract and other intraocular lens replacement procedures), GDP +5% (announces Tuscaloosa Marine Shale well result and operational update),TTM +3.2% (still checking), GCI +2.5% (following positive Barron's mention), SFY +2.3% (announces New Eagle Ford Well tests; average initial production rate of 21.4 mln cubic feet of gas per day), VPCO +1.8% (FDA considering options for regulations on E cigs, according to reports).
Analyst comments: AAV +4% (upgraded to Outperform at RBC Capital Mkts), TRIP +2.9% (upgraded to Outperform from Sector Perform at Pacific Crest), CENX +2.5% (upgraded to Neutral from Underperform at BofA/Merrill), MHR +2.2% (upgraded to Buy from Hold at Stifel), KTWO +2% (initiated with an Outperform at Cowen), GLOP +1.4% (initiated with a Outperform at Credit Suisse),MTN +1.3% (upgraded to Overweight from Equal Weight at Evercore), CMG +1.1% (TAG raises FY14 EPS est above consensus), MNTA +1.1% (resumed with a Buy at Goldman), AA +0.9% (upgraded to Neutral from Underperform at BofA/Merrill
)
In reaction to strong earnings/guidance: CONN +10.7%.
M&A news: NPSP +18.7% (Shire (SHPG) has secured funding for $5 bln NPSP bid, according to reports), PL +17.7% (Dai-ichi Life Insurance considering acquisition of PL, according to reports), BRCM +14% (to explore strategic alternatives for Cellular Baseband Business; reaffirms Q2 revenue guidance), HCT +10.9% (to be acquired by Ventas (VTR) for $2.6 bln, or $11.33 per HCT share),AMRI +3.1% (to acquire Oso Biopharmaceuticals Manufacturing for $110 million in cash; co anticipates the acquisition will be accretive to 2014 earnings), AHL +2.6% (Endurance Specialty (ENH) increases Proposal to Acquire Aspen Insurance Holdings (AHL) to $49.50 Per Share in Cash), SQNM +2% (announces its bioscience business was acquired by Agena Bioscience).
Select Biotech/pharma related names showing strength following ASCO: ARIA +14.6%, IMUC +11.9%, PCYC +6.8%, AVEO +5.4%, RXDX +3.6%, PBMD +0.7%, AZN +0.7%, BMY +0.5%.
Other news: LIQD +7.4% (MSDC Management discloses 10.6% passive stake in 13G filing), CANF +6.3% (announces that the US FDA has agreed with its Phase ii liver cancer protocol ), OMER +6.2% (receives FDA approval of Omidria for use in cataract and other intraocular lens replacement procedures), GDP +5% (announces Tuscaloosa Marine Shale well result and operational update),TTM +3.2% (still checking), GCI +2.5% (following positive Barron's mention), SFY +2.3% (announces New Eagle Ford Well tests; average initial production rate of 21.4 mln cubic feet of gas per day), VPCO +1.8% (FDA considering options for regulations on E cigs, according to reports).
Analyst comments: AAV +4% (upgraded to Outperform at RBC Capital Mkts), TRIP +2.9% (upgraded to Outperform from Sector Perform at Pacific Crest), CENX +2.5% (upgraded to Neutral from Underperform at BofA/Merrill), MHR +2.2% (upgraded to Buy from Hold at Stifel), KTWO +2% (initiated with an Outperform at Cowen), GLOP +1.4% (initiated with a Outperform at Credit Suisse),MTN +1.3% (upgraded to Overweight from Equal Weight at Evercore), CMG +1.1% (TAG raises FY14 EPS est above consensus), MNTA +1.1% (resumed with a Buy at Goldman), AA +0.9% (upgraded to Neutral from Underperform at BofA/Merrill
)